Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy

• Status: Enrolling by invitation
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate long-term safety in participants with metastasis solid tumors that are benefitting from continuation with sacituzumab govitecan-hziy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gilead Sciences; Immunomedics, Inc.
• Treatments: Camptothecin; Immunoconjugates

Criteria

Key Inclusion Criteria:

• Receiving ongoing treatment with sacituzumab govitecan-hziy in a Gilead sponsored parent study that is closing

• Continuing to receive clinical benefit from sacituzumab govitecan-hziy therapy

Key Exclusion Criteria:

• Females who are pregnant or lactating

• Initiated therapy with another cancer therapeutic agent since receiving last dose of study drug on the Gilead sponsored study in which they participated

• Experienced a toxicity from sacituzumab govitecan-hziy that resulted in permanent discontinuation of therapy

• Have other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.